TheraRadar
← Back
Data updated: Jun 28, 2026

GENERAL AIR SERVICE & SUPPLY COMPANY

Pharma
Pharmaceuticals

GENERAL AIR SERVICE & SUPPLY COMPANY is a pharmaceutical company with 2 FDA-approved products.

2021
Since
2
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules

GENERAL AIR SERVICE & SUPPLY COMPANY's Key Drugs

GENERAL AIR SERVICE & SUPPLY COMPANY's core commercial portfolio centers on HELIUM, USP — its most strategically important drugs approved in the last 15 years.

GENERAL AIR SERVICE & SUPPLY COMPANY's Recent FDA Approvals

GENERAL AIR SERVICE & SUPPLY COMPANY secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

GENERAL AIR SERVICE & SUPPLY COMPANY's Therapeutic Areas

Disease areas where GENERAL AIR SERVICE & SUPPLY COMPANY has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.

No indication data

GENERAL AIR SERVICE & SUPPLY COMPANY Pipeline Snapshot

Active clinical trials for GENERAL AIR SERVICE & SUPPLY COMPANY across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • HELIUM, USP leads revenue
  • Drug-level revenue analysis

Trial Catalysts

  • Active trial monitoring
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling